Echinaforce Junior Bioavailability Trial

Summary

In this bioavailability trial should be shown that the one of the main active constituent in alcoholic echinacea extracts, the alkylamide dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamide (short: tetraen) is bioavailable in children of different age groups after intake of 5 Echinaforce junior tablets.

Timeline

Start

2017-02-20

Primary completion

2018-06-30

Completion

2018-06-30

Outcome

Outcome not reported

Stopped (Enrollment): “no participants could be recruited who were eager to donate blood for bioavailability despite prolongation of the study period.”

Drugs

Indications